Compounding: Hamburg, Dems Look To Shift Spotlight Away From FDA As Hearing Looms
This article was originally published in The Pink Sheet Daily
After a House subcommittee announces hearing focused on whether FDA could have prevented the meningitis outbreak at the New England Compounding Center, FDA commissioner and subcommittee Democrats write about apparent outside efforts to sidestep and delay compounder inspections.
You may also be interested in...
Iowa has contracted with a national pharmacy group to inspect facilities outside its borders. Although the program could serve as a potential model for a nationwide plan, it also could bring several problems.
Agency releases 483 forms from a post-crises inspection push; the effort may help FDA illustrate its inspection capabilities to Congress and states and indicate the agency’s oversight plans under the new authority it has proposed.
Sotagliflozin Hail Mary? Lexicon Seeks Opportunity For Formal Hearing On FDA Intent To Deny Approval
After complete response letter, Lexicon triggers rarely used mechanism for formal hearing, prompting US FDA to publicly list its problems with the proposed type 1 diabetes drug, for which Sanofi had originally sought approval.